Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
LUNAR-2: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields TTFields, 150 kHz Concomitant with Pembrolizumab and Platinum Based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
Study Type: Treatment
Phase: III
NCTID: NCT06216301
Principal Investigator:
Chao Huang
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer Lung-MAP Screening Study
Study Type: Screening
Phase: III
NCTID: NCT03851445
Principal Investigator:
Anusha Chidharla
A Randomized Phase II Study of INC280 capmatinib plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, METAmplified Stage IV or Recurrent Non-Small Cell Lung Cancer Lung-MAP Sub-Study
Study Type: Treatment
Phase: II
NCTID: NCT05642572
Principal Investigator:
Anusha Chidharla
Using Microbiome to Predict Durvalumab Toxicity in Post-CCRT NSCLC Patients MicroDurva
Study Type: Basic Science
Phase: IV
NCTID: NCT04680377
Principal Investigator:
Chao Huang
Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer
Study Type: Treatment
Phase: III
NCTID: NCT05624996
Principal Investigator:
Krishna Reddy
A Phase IIb, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer COPERNICUS
Study Type: Treatment
Phase: II
NCTID: NCT06667076
Principal Investigator:
Chao Huang
PRISM: PRecIsion in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab with or Without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer ES-SCLC
Study Type: Treatment
Phase: II
NCTID: NCT06769126
Principal Investigator:
Anusha Chidharla
A Phase I Dose Finding and Phase II Randomized Trial of Iadademstat Combined with Immune Checkpoint Inhibition Maintenance After Initial Chemoimmunotherapy in Patients with Extensive-Stage Small Cell Lung Cancer
Study Type: Treatment
Phase: I/II
NCTID: NCT06287775
Principal Investigator:
Chao Huang
Prospective Treatment of Types I, II and III Pleuropulmonary Blastoma PPB
Study Type: Treatment
Phase: III
NCTID: NCT06647953
Principal Investigator:
Keith August
A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable older adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
Study Type: Treatment
Phase: III
NCTID: NCT06096844
Principal Investigator:
Anusha Chidharla